Britain and America have concluded a important bilateral deal that will maintain no import taxes on UK medicine exports going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise spending on medicines through the NHS. This commitment ensures that tariffs on these vital products will stay at zero for a timeframe of 36 months.
This deal comes after earlier warnings to hike tariffs on patented drug imports, with figures floated as high as one hundred percent.
"This agreement with the United Kingdom reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement noted.
Trade Importance
Pharmaceuticals represent one of the Britain's most significant goods shipped to the United States, which is easily the primary destination for leading British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of September, the UK exported drugs totaling over eleven billion pounds to the US. This amount accounted for a significant portion of all goods exports in that span.
"This agreement secures jobs, boosts funding and paves the way for the UK to establish itself as a international leader for medical research," a minister commented.
Specific UK Commitments
The deal involves several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds topped 20%.
Broader Context
This agreement comes amid a protracted row between the sector and the ministers over spending levels and approval rates.
The disagreement were exacerbated by arguments that US consumers were charged several times more for the equivalent treatments than consumers in the other developed nations.
In recent months, several significant drug company projects in the UK have been halted or abandoned, while substantial expansions have been directed toward projects in the United States.
One official acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
